Actively Recruiting
Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck
Led by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Updated on 2023-12-11
400
Participants Needed
5
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on patients with squamous cell carcinoma of the head and neck who are treated with molecular targeted therapies. The study aims to collect plasma samples to explore biomarkers that might help predict how well treatments like cetuximab or other targeted agents work or if resistance to these treatments develops. This observational effort is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Participants are grouped based on their treatment type: those receiving radiation therapy combined with cetuximab, those treated with cetuximab and chemotherapy, and those involved in clinical studies using other molecular targeted agents. Plasma samples will be collected at the start of treatment, throughout the treatment period at each radiological evaluation, and at disease progression. During the study, researchers will prospectively store plasma samples for at least one year after collection to analyze potential biomarkers. Participants will provide blood samples at multiple points, and the research team will monitor treatment progress through regular radiological assessments. The total duration of participation varies depending on the treatment and follow-up schedules.
CONDITIONS
Brief Title
Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated with radiation therapy and cetuximab according to Bonner et al
- Patients treated with cetuximab in combination with chemotherapy according to Vermorken et al.
- Patients treated with a molecular targeted agent as a part of a clinical study
You will not qualify if you...
- Patients with another type of head and neck cancer
- Patients not treated with targeted therapies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Duration of treatment and follow-up period
Participants have plasma samples collected at baseline, during treatment with targeted therapies, and at disease progression to study biomarkers.
At baseline and during every radiological evaluation
Trial Site Locations
Total: 5 locations
1
Clinique Saint-Pierre
Ottignies, Brabant Wallon, Belgium, 1340
Actively Recruiting
2
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium, 6000
Actively Recruiting
3
Centre Hospitalier Jolimont-Lobbes-Nivelles-Tubize
Haine-Saint-Paul, Belgium, 7100
Actively Recruiting
4
CHU Liège
Liège, Belgium, 4000
Actively Recruiting
5
Clinique et Maternité Sainte-Elisabeth
Namur, Belgium, 5000
Actively Recruiting
Research Team
J
Jean-Pascal Machiels, MD, PhD
S
Séverine Carlier, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here